Evommune EVMN
NYSE EVMN
$5.18 -0.20 (-3.72%)
As of: Oct 21, 2026 · 3:59 PM EDT

Evommune (EVMN) EBITDA (2024 - 2026)

Updated

Evommune's EBITDA came in at -$34.34 million for Q2 2026, compared with -$22.62 million a year earlier.

Analysis

Evommune (EVMN) EBITDA (2024 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Evommune reported EBITDA of -$100.36 million; for FY2025, it was -$79.68 million.

  • Going back by year, EBITDA was -$68.73 million in FY2024.
  • Business Quant data shows EVMN's EBITDA at -$23.61 million (Q1 2026), -$29.39 million (Q4 2025) and -$13.02 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 12.29 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 9.10 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 8.33 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 999.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 5.09 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 4.63 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -9.70 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 5.89 Bn
10 Evommune 186.46 Mn -451.06 Mn - -34.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -34.34 Mn
Mar 31, 2026 -23.61 Mn
Dec 31, 2025 -29.39 Mn
Sep 30, 2025 -13.02 Mn
Jun 30, 2025 -22.62 Mn
Mar 31, 2025 -14.66 Mn
Dec 31, 2024 -21.09 Mn
API Access

Evommune EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=EVMN&period=max&api_key=YOUR_API_KEY